In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $14.87 in the prior trading day, Caredx Inc (NASDAQ: CDNA) closed at $14.93, up 0.40%. In other words, the price has increased by $0.40 from its previous closing price. On the day, 1.58 million shares were traded. CDNA stock price reached its highest trading level at $15.165 during the session, while it also had its lowest trading level at $14.62.
Ratios:
Our goal is to gain a better understanding of CDNA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.27 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 66.89. For the most recent quarter (mrq), Quick Ratio is recorded 3.00 and its Current Ratio is at 3.30. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On January 15, 2025, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight and also lowered its target price recommendation from $28 to $24.
On August 28, 2024, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $28.Wells Fargo initiated its Underweight rating on August 28, 2024, with a $28 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 05 ’25 when Novack Jeffrey Adam sold 2,688 shares for $12.79 per share. The transaction valued at 34,381 led to the insider holds 112,930 shares of the business.
Jeffrey Adam Novack bought 2,688 shares of CDNA for $33,869 on Aug 05 ’25. On Jul 07 ’25, another insider, Maag Peter, who serves as the Director of the company, sold 10,000 shares for $18.58 each. As a result, the insider received 185,831 and left with 308,846 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDNA now has a Market Capitalization of 794678336 and an Enterprise Value of 637545344. As of this moment, Caredx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.33 while its Price-to-Book (P/B) ratio in mrq is 2.43. Its current Enterprise Value per Revenue stands at 1.871 whereas that against EBITDA is -22.376.
Stock Price History:
The Beta on a monthly basis for CDNA is 2.37, which has changed by -0.5218575 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, CDNA has reached a high of $32.97, while it has fallen to a 52-week low of $10.96. The 50-Day Moving Average of the stock is 13.70%, while the 200-Day Moving Average is calculated to be -17.75%.
Shares Statistics:
The stock has traded on average 1.68M shares per day over the past 3-months and 1509550 shares per day over the last 10 days, according to various share statistics. A total of 53.22M shares are outstanding, with a floating share count of 50.25M. Insiders hold about 5.60% of the company’s shares, while institutions hold 103.49% stake in the company. Shares short for CDNA as of 1757894400 were 6484600 with a Short Ratio of 3.86, compared to 1755216000 on 6472810. Therefore, it implies a Short% of Shares Outstanding of 6484600 and a Short% of Float of 12.47.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Caredx Inc (CDNA).The consensus estimate for the next quarter is $0.2, with high estimates of $0.23 and low estimates of $0.17.
Analysts are recommending an EPS of between $0.57 and $0.48 for the fiscal current year, implying an average EPS of $0.54. EPS for the following year is $0.8, with 6.0 analysts recommending between $0.93 and $0.73.
Revenue Estimates
8 analysts predict $95.25M in revenue for . The current quarter. It ranges from a high estimate of $96.52M to a low estimate of $93.69M. As of . The current estimate, Caredx Inc’s year-ago sales were $82.88MFor the next quarter, 8 analysts are estimating revenue of $102.27M. There is a high estimate of $103.94M for the next quarter, whereas the lowest estimate is $101.42M.
A total of 8 analysts have provided revenue estimates for CDNA’s current fiscal year. The highest revenue estimate was $370.9M, while the lowest revenue estimate was $367.11M, resulting in an average revenue estimate of $368.86M. In the same quarter a year ago, actual revenue was $333.79MBased on 8 analysts’ estimates, the company’s revenue will be $412.73M in the next fiscal year. The high estimate is $425.48M and the low estimate is $394.4M.
